Skip to main content
Fig. 4 | The Journal of Headache and Pain

Fig. 4

From: Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial

Fig. 4

Distribution of RespondersT13 according to MIDAS and MMDs reductions after 3 months of erenumab administration. MIDAS: MIgraine Disability Assessment. MMDs: monthly migraine days. RespondersT13: patients with a MMDs reduction from baseline of at least 50% in the last 4 weeks of observation period (after 13 erenumab administrations). The p-value in the box was calculated with a χ2 test. The tables in the top of the figure show the sensibility and specificity of being RespondersT13 according to reduction of at least 50% in MIDAS, MMDs, or "either MIDAS or MMDs". The green shadows in the tables highlight the parameters with the best accuracy in sensibility or specificity

Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us